Option chain shows key data for TransCode Therapeutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for TransCode Therapeutics.

TransCode Therapeutics (NASDAQ:RNAZ) Stock, Option Chain

TransCode Therapeutics

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disease. It is committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode is developing a portfolio of first-in-class RNA therapeutic candidates designed to overcome the challenges of RNA delivery and thus unlock therapeutic access to a variety of novel genetic targets that could be relevant to treating a variety of cancers.

Crude Oil 6- logo

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

CRVS

KULR

PLRZ

RNAZ

Crude Oil Gains Over 1%, General Mills Shares Fall

Wall Street Bulls

LITM

NVNI

Dow Surges 150 Points, US Current Account Deficit Widens In Q3

TransCode Therapeutics shares are trading lower by 16% during Monday&#39;s session. The company announced a 1-for-33 reverse stock split.

Why TransCode Therapeutics (RNAZ) Stock Is Diving

TransCode Therapeutics, Inc. - Common Stock

TransCode Therapeutics Inc

D.A. Davidson &amp; Co. analyst Alexander Platt initiated coverage on IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Buy rating <a target="_blank" href="https://www.benzinga.com/quote/IONQ/analyst-ratings" rel="noreferrer noopener">and price target of $50</a>.
The analyst sees IonQ as a standout pure-play investment poised to benefit from the quantum computing sector&#8217;s rapid expansion, fueled by the limitations of classical computing in tackling complex problems.
IonQ&#8217;s core advantage lies in its trapped-ion qubit architecture, which delivers superior reliability, accuracy, and scalability compared to rival designs, adds the analyst.
Platt says that unlike IBM, Google, and others facing challenges with inconsistencies and short operational lifespans, IonQ leverages stable atomic properties for greater precision and extended performance times.
This approach reduces errors, enables more complex calculations, and simplifies system connectivity, allowing IonQ to tackle a wider array of problems effectively, writes the analyst.
The analyst says that Quantum Computing as a Service offers significant growth potential by providing access to quantum processing units without the need for upfront hardware investment.
IonQ&#8217;s Quantum Cloud platform and Hybrid Services allow enterprises to leverage quantum-enhanced solutions and integrate quantum and classical computing, adds the analyst.
Investors can gain exposure to the stock via Defiance Quantum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTUM#NASDAQ">QTUM</a>) and Spear Alpha ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRX#NASDAQ">SPRX</a>).
Price Action: IONQ shares are down 0.67% at $37.25 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42569883/quantum-computing-rigetti-d-wave-skyrocket-up-to-300-in-5-sessions-after-google-unveils-willow-chip-but-analysts-urge-caution-not-every-tiktok-guitarist-is-the-next-taylor-swift" target="_blank" rel="noreferrer noopener">Quantum Computing, Rigetti, D-Wave Skyrocket Up To 300% In 5 Sessions After Google Unveils Willow Chip, But Analysts Urge Caution: &#8216;Not Every TikTok Guitarist Is The Next Taylor Swift&#8217;</a></li>
</ul>
Image: Courtesy of IonQ.

Analyst Color

Mid Cap

Price Target

Initiation

Analyst Ratings

Movers

IONQ

QTUM

SPRX

IonQ Positioned To Dominate Quantum Computing Era: Analyst Highlights Unique Trapped-Ion Advantage

On Thursday, Vertex Pharmaceuticals Incorporated&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) announced results from its Phase 2 study of suzetrigine for painful lumbosacral radiculopathy (LSR), a disorder that causes pain in the lower back and hip&nbsp;that radiates down the back of the thigh into the leg.
The study met its primary endpoint with a statistically significant and clinically meaningful reduction in pain on the numeric<a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42571378/vertex-announces-results-from-phase-2-study-of-suzetrigine-for-the-treatment-of-painful-lumbosacra" rel="noreferrer noopener"> pain rating scale (NPRS)</a>.
The suzetrigine arm showed a statistically significant and clinically meaningful within-group reduction in pain from baseline, with a mean change in NPRS at Week 12 of -2.02.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42396975/vertex-has-5-billion-plus-opportunity-in-pain-and-kidney-disease-programs-analyst-upgrades-stock" rel="noreferrer noopener">Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock</a>
The study also included a placebo reference arm, which showed a similar within-group reduction in pain from baseline, with a mean change in NPRS at Week 12 of -1.98.
Secondary and other endpoints were consistent with the study&#8217;s primary endpoint.
Vertex also conducted post-hoc analyses showing variability in the placebo response across study sites, a recognized issue in pain trials.
In the ~40% of sites that had lower placebo responses, the suzetrigine arm within-group reduction in pain was similar to the overall study and had greater separation from the placebo arm.
These analyses suggest that trial design innovation may better control the placebo response and separate the treatment effect of suzetrigine from placebo in future studies, which Vertex will incorporate as it designs the pivotal program.
Suzetrigine was generally well tolerated in the study. William Blair notes that Vertex plans to move suzetrigine into Phase 3 trials following discussions with regulators despite Phase 2 results not clearly outperforming a placebo.
The analyst questions the decision, citing concerns about the trial&#8217;s design and the small effect size, which could make it hard to ensure success.
Price Action: VRTX stock is down 13.4% at $387.37 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42598739/omeros-antibody-improves-overall-survival-in-rare-complication-after-stem-cell-transplant-stock-surges" target="_blank" rel="noreferrer noopener">Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges</a></li>
</ul>

Biotech

Health Care

General

VRTX

Why Is Vertex Pharmaceuticals Stock Trading Lower On Thursday After Back Pain Trial Data?

Citigroup analyst Scott Gruber maintains Schlumberger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) with a Buy and lowers the price target from $53 to $50.

Citigroup Maintains Buy on Schlumberger, Lowers Price Target to $50

Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) have been partners in an electric delivery van deal since the EV company <a href="https://www.benzinga.com/trading-ideas/long-ideas/21/11/24017625/amazon-doubling-down-on-rivian-ipo-what-investors-need-to-know">went public in 2021</a>. Here's a look at the recent milestone hit and what's next for both companies.
What Happened: Amazon partnered with Rivian, a <a href="https://www.benzinga.com/markets/equities/24/06/39529434/rivian-investor-day-highlights-ceo-scaringe-focuses-on-amazon-tesla-partnerships-says-ev-chargin">company it invested in</a> prior to the 2021 IPO, on a deal for 100,000 electric delivery vehicles with a goal to have all the vehicles on the road by 2030.
With six years left to go, Amazon is one-fifth of the way to that goal, which is part of an overall Climate Pledge to have net-zero carbon emissions by 2040.
Amazon had its first Rivian EDV on the road in 2022 and now has over 20,000 of the Rivian vehicles in its fleet, according to a report from <a href="https://www.teslarati.com/amazon-announces-major-milestone-in-ev-transition-with-rivian/amp/">Teslarati</a>.
While the majority of the vehicles are operating in the United States, Amazon is also using the electric delivery vans in Europe.
For Amazon, the use of the electric delivery vans gets the company closer to its goal of net-zero carbon emissions, while also making things more efficient for drivers.
In 2024, over one billion Amazon packages have been delivered using the Rivian electric delivery vans.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41825787/rivian-q3-earnings-highlights-revenue-eps-miss-ceo-confident-in-q4-gross-profit-r2-being-fundamenta">Rivian Q3 Earnings Highlights: Revenue, EPS Miss, CEO Confident In Q4 Gross Profit, R2 Being &#8216;Fundamental Driver&#8217; Of Growth</a>
What's Next: Though the 20,000 milestone may only be one-fifth of the way to the 100,000 goal, it has been rapidly increasing. In March 2023, Amazon had only 3,000 of the Rivian vans in its fleet according to the report.
Amazon will continue to anticipate deliveries of the Rivian vehicles to meet its climate goals and to streamline driver efficiency.
For Rivian, the Amazon 100,000 unit order remains a key priority and can help provide a strong cushion of production and delivery unit figures as it awaits its new consumer vehicle models.
Rivian CEO RJ Scaringe shared earlier this year that the electric delivery vans for Amazon rolled out slower than anticipated.
Back in November 2023, Rivian announced that it had <a href="https://www.benzinga.com/news/earnings/23/11/35659331/rivian-stock-upshifts-on-strong-q3-earnings-eps-beat-revenue-beat-increased-production-guidance-and">amended its deal</a> with Amazon to no longer be exclusive.
"We have amended our Amazon agreement with terms and conditions, which provide the opportunity to sell commercial vans to other customers, helping more companies reduce their CO2 emissions," Scaringe said at the time.
Rivian also said at the time that it was in "active discussions" with other potential EDV fleet customers. In December 2023, Rivian announced a deal with AT&amp;T Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/T#NYSE">T</a>).
Amazon remains a large shareholder in Rivian with a reported stake of around 16%. The e-commerce leader will continue to collect deliveries of Rivian EDVs.
For Rivian, the company will deliver vehicles to Amazon and also look to diversify to other customers as it grows its EDV segment alongside its consumer vehicle division.
RIVN Price Action: Rivian stock is down 1% to $12.98 on Thursday versus a 52-week trading range of $8.26 to $24.61. Rivian stock is down 39% year-to-date in 2024 and down around 90% since its market debut in 2021.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/equities/23/10/35235038/rivian-ceo-rj-scaringe-reveals-big-question-jeff-bezos-had-before-amazon-picked-up-stake-in-ev-s">Rivian CEO RJ Scaringe Reveals Big Question Jeff Bezos Had Before Amazon Picked Up Stake In EV Startup: &#8216;Do We Understand The Chessboard?</a></li>
</ul>
Photo: Amazon

AMZN

RIVN

Amazon Has 20,000 Rivian Electric Delivery Vans In Fleet: Here's What Could Be Next For Both Companies

The story of Ilya Lichtenstein, known for his role in <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42055570/bitfinex-bitcoin-laundering-case-lands-crocodile-of-wall-street-in-jail">the Bitfinex hack</a>, and his wife Heather &#8220;Razzlekhan&#8221; Morgan has taken a new turn following the release of the Netflix documentary, &#8220;Biggest Heist Ever.&#8221;
In a video <a href="https://x.com/unrealdutch/status/1869713981591663003">statement </a>from jail, Lichtenstein confessed to his crimes, expressed regret, and outlined his future plans in cybersecurity, while Morgan pivots her notoriety into new entrepreneurial avenues.
Ilya Lichtenstein&#8217;s Confession:
In the wake of the documentary&#8217;s worldwide attention, Lichtenstein took the opportunity to set the record straight. &#8220;I hacked Bitfinex, I stole and laundered thousands of Bitcoin, and I am so sorry for everything,&#8221; he admitted, aiming to dismantle years of misinformation surrounding the hack. 
His statement reflects a deep sense of remorse as he looks to make amends, stating, &#8220;I can&#8217;t change the past, but I can and will do everything I can to make amends.&#8221;
Towards a Career In Cybersecurity:
Lichtenstein is planning to use his hacking skills for positive impact. &#8220;Nobody knows the dark web better than someone who has spent years navigating it,&#8221; he explained, aiming to leverage this knowledge in cybersecurity. 
His ambition to work in cybersecurity post-incarceration paints a narrative of redemption, suggesting that those with a background in hacking might contribute to digital security in meaningful ways.
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42585798/stephen-colbert-jokes-fartcoin-is-silent-but-wealthy-as-meme-coin-hits-1-billion-all-time-high-valuation">Stephen Colbert Jokes Fartcoin Is &#8216;Silent But Wealthy&#8217; As Meme Coin Hits $1 Billion All-Time High Valuation</a>
Heather Morgan&#8217;s Cameo Venture:
Simultaneously, Heather Morgan, whose involvement in the Bitcoin laundering conspiracy led to her sentence, is taking her digital celebrity in a new direction. 
After the documentary heightened public interest in their story, Morgan started offering personalized videos on Cameo under her rapper alias &#8216;Razzlekhan.&#8217; 
This move not only leverages her infamy but also showcases the couple&#8217;s divergent paths towards rehabilitation and entrepreneurship.
Exploring Themes From The Documentary:
&#8220;Biggest Heist Ever&#8221; on Netflix brought to light several themes that resonate with current discussions in the crypto space:
<ul>
<li>Security Vulnerabilities: The documentary highlighted how even well-secured platforms like Bitfinex can be compromised, emphasizing the need for continual improvement in security protocols.</li>
<li>Investor Risk Awareness: The narrative serves as a stark reminder of the risks associated with digital assets, urging investors to be cautious and informed about where they store their cryptocurrencies.</li>
<li>Redemption and Repurposing: Lichtenstein&#8217;s pivot towards cybersecurity post-documentary reflects a broader narrative of how past misdeeds can be turned into opportunities for positive change.</li>
<li>Media Influence: The documentary&#8217;s portrayal of the couple has influenced public perception, providing a platform for both Lichtenstein&#8217;s plea for redemption and Morgan&#8217;s entrepreneurial endeavors.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42573095/bitcoin-reserve-could-call-us-solvency-into-question-critic-says-vaneck-exec-fires-back-this-is-loserthink">Bitcoin Reserve Could Call US Solvency Into Question Critic Says, VanEck Exec Fires Back: &#8216;This Is Loserthink&#8217;</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Bitfinex Hacker Of 'Biggest Heist Ever' Documentary Takes Responsibility—But His Wife Has Other Ideas

Citigroup analyst Thomas Palmer maintains General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) with a Neutral and lowers the price target from $71 to $67.

Citigroup Maintains Neutral on General Mills, Lowers Price Target to $67

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Zymeworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYME#NASDAQ">ZYME</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.3, a high estimate of $28.00, and a low estimate of $12.00. Witnessing a positive shift, the current average has risen by 25.38% from the previous average price target of $13.00.
<img src="https://www.benzinga.com/files/images/story/2024/1734631264_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The analysis of recent analyst actions sheds light on the perception of Zymeworks by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$14.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Brian Cheng</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Andrew Berens</td>
<td>Leerink Partners</td>
<td>Raises</td>
<td>Outperform</td>
<td>$25.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Stephen Willey</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Robert Burns</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Zymeworks. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Zymeworks compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Zymeworks's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Zymeworks's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ZYME/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Zymeworks analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Zymeworks</h2>
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
<h3>Zymeworks's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Zymeworks's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -3.07% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -186.56%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -7.72%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Zymeworks's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -5.95%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Zymeworks's debt-to-equity ratio is below the industry average at 0.06, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ZYME

Deep Dive Into Zymeworks Stock: Analyst Perspectives (10 Ratings)

Piper Sandler analyst Arvind Ramnani maintains Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) with a Overweight and raises the price target from $422 to $429.

Piper Sandler Maintains Overweight on Accenture, Raises Price Target to $429

During the last three months, 5 analysts shared their evaluations of Churchill Downs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHDN#NASDAQ">CHDN</a>), revealing diverse outlooks from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $163.2, a high estimate of $168.00, and a low estimate of $151.00. The current average, unchanged from the previous average price target, holds steady. 
<img src="https://www.benzinga.com/files/images/story/2024/1734631253_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Churchill Downs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$166.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Barry Jonas</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$165.00</td>
<td>$166.00</td>
</tr>
<tr>
<td>Ben Chaiken</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$151.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Daniel Politzer</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$161.00</td>
</tr>
<tr>
<td>Jordan Bender</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$166.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Churchill Downs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Churchill Downs compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Churchill Downs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Churchill Downs's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CHDN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Churchill Downs analyst ratings.</a>
<h2>All You Need to Know About Churchill Downs</h2>
Churchill Downs Inc is a gaming entertainment, online wagering, and racing company. It operates through three business segments: Live and Historical Racing, TwinSpires, and Gaming. The Live and Historical Racing segment includes live and historical pari-mutuel racing. The TwinSpires segment includes the revenue and expenses for online horse racing and the online and retail sports betting and iGaming wagering business. The Gaming segment includes revenue and expenses for the casino properties and associated racetracks that support the casino license. The Gaming segment generates revenue and expenses from slot machines, table games, video lottery terminals, video poker, HRMs, ancillary food and beverage services, hotel services, commission on pari-mutuel wagering, and racing events.
<h3>Churchill Downs's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Churchill Downs displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 9.78%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Churchill Downs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.41% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Churchill Downs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.15% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Churchill Downs's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.91%, the company showcases efficient use of assets and strong financial health.
Debt Management: Churchill Downs's debt-to-equity ratio is below the industry average. With a ratio of 4.41, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CHDN

A Glimpse Into The Expert Outlook On Churchill Downs Through 5 Analysts

In the preceding three months, 12 analysts have released ratings for Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>), presenting a wide array of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $92.08, a high estimate of $115.00, and a low estimate of $70.00. Surpassing the previous average price target of $89.58, the current average has increased by 2.79%.
<img src="https://www.benzinga.com/files/images/story/2024/1734631242_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Western Digital's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$93.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$70.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$85.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matt Bryson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Medhi Hosseini</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$115.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Mark Miller</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$92.00</td>
<td>$92.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Western Digital. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Western Digital compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Western Digital's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Western Digital's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/WDC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Western Digital analyst ratings.</a>
<h2>Get to Know Western Digital Better</h2>
Western Digital is a leading vertically integrated supplier of data storage solutions, spanning both hard disk drives and solid-state drives. In the HDD market it forms a practical duopoly with Seagate, and it is the largest global producer of NAND flash chips for SSDs in a joint venture with competitor Kioxia.
<h3>Understanding the Numbers: Western Digital's Finances</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Western Digital showcased positive performance, achieving a revenue growth rate of 48.91% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.
Net Margin: Western Digital's net margin is impressive, surpassing industry averages. With a net margin of 11.75%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Western Digital's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.28%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Western Digital's ROA stands out, surpassing industry averages. With an impressive ROA of 1.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Western Digital's debt-to-equity ratio is below the industry average. With a ratio of 0.64, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Western Digital: Insights From 12 Financial Analysts

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on First Horizon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FHN#NYSE">FHN</a>) in the last three months.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">8</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $21.07, along with a high estimate of $25.00 and a low estimate of $17.00. Observing a 8.27% increase, the current average has risen from the previous average price target of $19.46. 
<img src="https://www.benzinga.com/files/images/story/2024/1734631230_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of First Horizon's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brady Gailey</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$24.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Nicholas Holowko</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$19.50</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$23.00</td>
<td>$22.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Ryan Nash</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$23.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Michael Rose</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$22.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Russell Gunther</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$20.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jared Shaw</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$21.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jon Arfstrom</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$20.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Steven Alexopoulos</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>John Pancari</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$18.00</td>
<td>$18.50</td>
</tr>
<tr>
<td>David Chiaverini</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$17.00</td>
<td>$20.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to First Horizon. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of First Horizon compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for First Horizon's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of First Horizon's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/FHN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on First Horizon analyst ratings.</a>
<h2>Delving into First Horizon's Background</h2>
First Horizon Corp is the parent company of First Tennessee Bank, a prominent regional bank with about 200 branches around Tennessee. The regional bank is responsible for roughly 65% of its revenue, while capital markets make a 25% contribution. The remainder is split between the firm's non-strategic (wind-down) and corporate operations. First Horizon concentrates on offering a variety of banking products mainly in its home state, where it has the second- largest deposit franchise with a 13% deposit market share.
<h3>Financial Milestones: First Horizon's Journey</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: First Horizon displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 5.94%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Net Margin: First Horizon's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 26.56%, the company may face hurdles in effective cost management.
Return on Equity (ROE): First Horizon's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 2.53%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): First Horizon's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: First Horizon's debt-to-equity ratio is below the industry average at 0.22, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: First Horizon Through The Eyes Of 14 Analysts

Citigroup analyst Alexander Hacking maintains Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>) with a Buy and lowers the price target from $160 to $145.

STLD

Citigroup Maintains Buy on Steel Dynamics, Lowers Price Target to $145

Western Alliance's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>) short percent of float has fallen 6.64% since its last report. The company recently reported that it has 6.48 million shares sold short, which is 6.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 8.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Western Alliance Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734631222_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Western Alliance has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Western Alliance's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Western Alliance's peer group average for short interest as a percentage of float is 3.54%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Western Alliance?

During the last three months, 5 analysts shared their evaluations of Camping World Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWH#NYSE">CWH</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $27.2, along with a high estimate of $30.00 and a low estimate of $24.00. This upward trend is evident, with the current average reflecting a 7.38% increase from the previous average price target of $25.33.
<img src="https://www.benzinga.com/files/images/story/2024/1734631222_0_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Camping World Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alex Perry</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Altobello</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$27.00</td>
<td>-</td>
</tr>
<tr>
<td>Scott Stember</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$28.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Noah Zatzkin</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$27.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Camping World Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Camping World Holdings compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Camping World Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CWH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Camping World Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Camping World Holdings</h2>
Camping World Holdings Inc is retailer of RVs and related products and services. The Company has the two reportable segments: Good Sam Services and Plans segment includes sale of emergency roadside assistance plans; commissions on property and casualty insurance programs; travel assist programs; extended vehicle service contracts; vehicle financing and refinancing assistance; consumer shows and events; and consumer publications and directories. RV and Outdoor Retail segment includes the sale of new and used RVs; commissions on the finance and insurance contracts related to the sale of RVs; the sale of RV service and collision work; the sale of RV parts, accessories, sale of outdoor products, equipment, gear and supplies; business to business distribution of RV furniture, etc.
<h3>Camping World Holdings: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3 months period, Camping World Holdings faced challenges, resulting in a decline of approximately -0.27% in revenue growth as of 30 September, 2024. This signifies a reduction in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.32%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Camping World Holdings's ROE stands out, surpassing industry averages. With an impressive ROE of 5.15%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Camping World Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.11%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 33.13, caution is advised due to increased financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Camping World Holdings Stock

CVS Health's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) short percent of float has fallen 17.06% since its last report. The company recently reported that it has 17.77 million shares sold short, which is 1.41% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.67 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>CVS Health Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734631217_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for CVS Health has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing CVS Health's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, CVS Health's peer group average for short interest as a percentage of float is 8.75%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into CVS Health's Recent Short Interest

Across the recent three months, 9 analysts have shared their insights on Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Tenable Holdings and provided 12-month price targets. The average target is $48.0, accompanied by a high estimate of $50.00 and a low estimate of $45.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 4.48%. 
<img src="https://www.benzinga.com/files/images/story/2024/1734631211_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
A clear picture of Tenable Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Hold</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$47.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$50.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$45.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Tenable Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tenable Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tenable Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Tenable Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/TENB/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tenable Holdings analyst ratings.</a>
<h2>Delving into Tenable Holdings's Background</h2>
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
<h3>Tenable Holdings: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Tenable Holdings displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.68%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: Tenable Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -4.06%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Tenable Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -2.4%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Tenable Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.01.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TENB

Deep Dive Into Tenable Holdings Stock: Analyst Perspectives (9 Ratings)

RTX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) short percent of float has fallen 27.27% since its last report. The company recently reported that it has 10.68 million shares sold short, which is 0.8% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.44 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>RTX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734631211_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RTX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing RTX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, RTX's peer group average for short interest as a percentage of float is 3.32%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into RTX's Recent Short Interest

Citigroup analyst Alexander Hacking maintains Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) with a Buy and lowers the price target from $240 to $160.

Citigroup Maintains Buy on Nucor, Lowers Price Target to $160

Piper Sandler analyst Derek Podhaizer initiates coverage on Ormat Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORA#NYSE">ORA</a>) with a Neutral rating and announces Price Target of $78.

Piper Sandler Initiates Coverage On Ormat Technologies with Neutral Rating, Announces Price Target of $78

Telsey Advisory Group analyst Dana Telsey reiterated the Outperform rating on Birkenstock Holding plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) <a target="_blank" href="https://www.benzinga.com/quote/BIRK/analyst-ratings" rel="noreferrer noopener">with a price forecast of $70.</a>
Yesterday, the company reported fourth-quarter&nbsp;fiscal 2024 results, with revenue growing&nbsp;22% year over year on a reported and constant currency <a target="_blank" href="https://www.benzinga.com/news/earnings/24/12/42549753/birkenstock-q4-earnings-beat-revenue-surge-margin-pressure-more" rel="noreferrer noopener">basis to 456 million euros.</a>
The analyst notes that management is observing positive momentum across the entire closed-toe category, ranging from clogs to boots.
In the U.S., Birkenstock is experiencing strong demand for clogs, particularly for the Boston and Tokyo silhouettes, as well as the newly introduced Lutry, which continues to perform well.
The solid demand for clogs has also positively impacted sales of the Zermatt slipper, which, despite being part of the product line for over five years, is now seeing increased demand due to the halo effect from the popularity of clogs.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/12/42597251/roche-prothena-partnered-mid-stage-parkinsons-trial-misses-primary-endpoint-but-cling-on-signs-of-clinical-benefits" rel="noreferrer noopener">Roche-Prothena Partnered Mid-Stage Parkinson&#8217;s Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits</a>
In Europe, lace-up styles and boots are outpacing other product categories. However, the analyst highlights that while closed-toe shoes are performing strongly, sandals still experienced double-digit growth during the same period.
Despite a challenging global macroeconomic environment, the brand continued to experience solid demand across various geographies and sales channels, successfully executing its strategy, Telsey notes.
The company sees FY25 revenue&nbsp;growth of 15% – 17% in constant currency, adjusted EBITDA margin of 30.8% – 31.3% (up 50 basis points) and capital&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">expenditures of around 80 million euros</a>.
The analyst highlights that the company&#8217;s FY25 outlook aligns with the long-term expectations initially communicated during its IPO process in late 2023.
With consumers becoming more selective in their purchases, the analyst views Birkenstock as a brand well-positioned to maintain its success in the market due to its high-end lifestyle positioning, offering comfort and a frictionless walking experience, which creates a competitive edge that is difficult to replicate.
The analyst states that the sales estimate for FY24 has been updated to 2.12 billion euros, reflecting a 17.2% year-over-year increase, slightly higher than the previous estimate of 2.09 billion euros, which represented a 15.9% increase.
Additionally, the forecast for FY24 adjusted EBITDA has been revised to 661.5 million euros, a slight increase from the prior estimate of 654.2 million euros.
Price Action: BIRK shares are trading lower by 0.98% to $56.60 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42561240/salesforces-ai-powered-agentforce-20-spurs-analyst-upgrades-and-growth-optimism" target="_blank" rel="noreferrer noopener">Wall Street Analysts Are Bullish On Salesforce&#8217;s AI Vision – Here&#8217;s Why</a></li>
</ul>
Image via Shutterstock.

Reiteration

BIRK

Birkenstock's High-end Lifestyle Positioning Provides Competitive Edge That Is Difficult To Replicate: Analyst

Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on TransCode Therapeutics (RNAZ – Research Report) and keeping the price target a...

TransCode Therapeutics: Buy Rating Backed by Strategic Focus and Promising Phase 1 Study

TransCode Therapeutics to conduct reverse stock split

TransCode Therapeutics (RNAZ) has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proce...

Transcode Therapeutics issues 21.2M shares at 37.7c in private placement

TransCode Therapeutics announces $8M private offering

TransCode Therapeutics ( ($RNAZ) ) has provided an update. TransCode Therapeutics has announced a 1-for-33 reverse stock split aimed at boosting it...

TransCode Therapeutics Announces Reverse Stock Split

TransCode Therapeutics to execute 1-for-33 reverse stock split on Dec 4

TransCode Therapeutics ( ($RNAZ) ) has shared an announcement. TransCode Therapeutics, Inc. recently executed a private placement agreement with in...

TransCode Therapeutics Raises $8M in Private Placement

19:50 EST Transcode Therapeutics (RNAZ) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-movi...

Transcode Therapeutics Inc trading halted, news pending

TransCode Therapeutics (RNAZ) announced that the Safety Review Committee, or SRC, monitoring its Phase 1 clinical trial has unanimously approved op...

Transcode announces SRC approved third cohort in TTX-MC138 clinical trial

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Viking Therapeutics (VKTX – Research Report) and Tra...

Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), TransCode Therapeutics (RNAZ)

VKTX

Press Releases

TransCode Therapeutics Announces Publication of Study with Lead Therapeutic Candidate Revealing Mechanisms Behind Candidate's Preclinical Efficacy Against Metastatic Cancer

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Completes Initial Dosing of First Cohort in Phase 1 Clinical Trial with TTX-MC138, a microRNA-Targeted Technology

TransCode Therapeutics Announces Safety Review Committee Approval of Second Cohort Opening in Phase 1 TTX-MC138 Clinical Trial Following Favorable Review of Cohort 1 Safety Data

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces 1-for-33 Reverse Stock Split

Financing

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Comments

TransCode Therapeutics

TransCode Therapeutics (RNAZ) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga